New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy

Figures & data

Figure 1. NIRF imaging of liver-implanted CT26 colon tumours. (a) Whole body images of athymic nude mice bearing CT26 colon tumours in their liver tissues after intravenous injection of Cy5.5-P-HA-NPs as a function of time. Arrows indicate the sites of tumours. (b) Ex vivo fluorescence images of tumour-bearing livers and organs excised at 48 h post injection of NPs (5 mg/kg). (c) Representative histological images of normal liver and tumour slices stained with haematoxylin and eosin [42]. Reprinted with permission from American Chemical Society (Copyright © 2011).

Figure 2. In vivo tumour inhibition study. Balb/c nude mice were injected with PBS, free paclitaxel and HA-CA-Paclitaxel at Day 0 (n = 3). Comparison of tumour size on Day 8 of (A) Control (B) Paclitaxel (C) HA-CA-Paclitaxel (2 mg/kg) (D) HA-CA-Paclitaxel (5 mg/kg). Tumour inhibition data show mean tumour volume, of triplicate samples ± SD. *p < .05 relative to HA-CA-paclitaxel (2 mg/kg) and **p < .05 relative to control group [70]. Reprinted with permission from Elsevier B.V. (Copyright © 2014) through Copyright Clearance Centre.

Choi KY, Yoon HY, Kim JH, et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano. 2011;5:8591–8599.

 PubMed Web of Science ®Google Scholar

Thomas RG, Moon M, Lee S, et al. Paclitaxel loaded hyaluronic acid nanoparticles for targeted cancer therapy: in vitro and in vivo analysis. Int J Biol Macromol. 2015;72:510–518.

 PubMed Web of Science ®Google Scholar